Genetic Factors in Aortic Stenosis and the Role of Testing

Last reviewed: May 12, 2026 Last updated: May 12, 2026

Written by: Jay Hastings , CEO of PlexusDx

Jay Hastings is the CEO of PlexusDx, a precision health company focused on genetic testing, blood biomarker insights, and personalized wellness recommendations. He has more than 20 years of experience across healthcare innovation, genomics, laboratory operations, healthcare investing, and strategic finance. His work has included scaling healthcare startups, leading CLIA lab integrations, and helping expand consumer access to precision health tools.

Medically reviewed by: Jayden Lee, PharmD, EMBA

Jayden Lee, PharmD, EMBA, is the PlexusDx Medical Science Liaison with a PharmD and MBA specializing in pharmacogenomics and clinical product development, with a proven ability to bridge the gap between genomic research and practical patient outcomes. Dr. Lee has more than 10 years of professional experience in clinical pharmacy, academia, and research.

This article is part of the PlexusDx Education Hub — your resource for evidence-based guidance on heart & cardiovascular health. Browse all Heart & Cardiovascular Health education

Aortic stenosis is a narrowing of the aortic valve, the gateway that lets blood flow from the heart's left ventricle into the aorta. As the valve stiffens or calcifies, the heart must work harder to push blood through the smaller opening, which over years can lead to symptoms like breathlessness, chest tightness, or fatigue. It is one of the most common valve conditions in older adults — and its development is shaped by both aging and inherited biology.

Researchers have identified specific genes that influence valve formation and calcification. Knowing this genetic context does not diagnose or treat the condition, but it helps explain why aortic stenosis sometimes appears earlier or clusters in families.

How Aortic Stenosis Develops

In most cases, aortic stenosis is a calcific process: over decades, calcium and lipid deposits accumulate on the valve leaflets, stiffening tissue that should open and close cleanly. This shares biological features with atherosclerosis, including inflammation and lipid deposition. A significant subset of cases traces to a bicuspid aortic valve — a valve with two leaflets instead of the usual three — which is the most common congenital heart difference and often has a genetic basis.

NOTCH1: Valve Development and Calcification

The NOTCH1 gene is the best-established single gene linked to aortic valve disease. NOTCH1 is part of a signaling pathway that guides how heart valves form during development and helps suppress calcification in mature valve tissue. Loss-of-function mutations in NOTCH1 have been identified in families with bicuspid aortic valve and early calcific aortic stenosis. When NOTCH1 signaling is disrupted, the brakes on valve calcification loosen — a direct mechanistic link between genetics and disease.

LPA and Lipoprotein(a): A Powerful Genetic Driver

One of the strongest genetic risk factors for calcific aortic valve disease comes from the LPA gene, which determines your blood level of lipoprotein(a), or Lp(a). Lp(a) is a cholesterol-carrying particle whose concentration is roughly 80–90% genetically determined and largely stable across life. Large genetic studies have found that variants raising Lp(a) also raise the risk of aortic valve calcification. Because Lp(a) is inherited and measurable with a simple blood test, it has become a focus of cardiovascular research and prevention discussions.

PALMD and Emerging Genetic Signals

Genome-wide studies have pointed to additional loci, including the PALMD gene (with the variant rs7543130 among the most replicated signals for calcific aortic stenosis). PALMD's exact role in valve biology is still being clarified, but its consistent appearance across populations underscores that aortic stenosis is polygenic — shaped by many variants of small-to-moderate effect, not a single switch. This is why family history and multiple genetic factors together paint a fuller risk picture than any one gene.

The Role of Genetic Insight and Provider Care

Genetic context is educational, not a substitute for cardiology. Diagnosis of aortic stenosis relies on a clinician's exam and imaging such as echocardiography; management decisions belong entirely to a qualified provider. Where genetics adds value is in understanding baseline biology — for example, awareness of an inherited Lp(a) tendency can prompt an informed conversation about cardiovascular risk factors you can influence, like blood pressure, lipids, and lifestyle. The PlexusDx Precision Peptide Genetic Test analyzes 14 pathways, 49 peptides, 150+ genetic insights, offering pathway-level context about your biology. It does not diagnose, treat, or predict aortic stenosis; it gives you and your provider more information to work with.

Frequently Asked Questions

Is aortic stenosis genetic?

Partly. Aging and calcification drive most cases, but genetics contributes meaningfully. NOTCH1 mutations are linked to bicuspid aortic valve and early calcific disease, and inherited lipoprotein(a) levels from the LPA gene raise valve-calcification risk. Aortic stenosis is polygenic, so many variants and lifestyle factors interact.

What is the NOTCH1 gene's role in aortic stenosis?

NOTCH1 guides how heart valves form and helps suppress valve calcification in adulthood. Loss-of-function NOTCH1 mutations have been found in families with bicuspid aortic valve and early aortic stenosis, making it the best-established single gene linked to this valve condition in the research literature.

Can genetic testing diagnose aortic stenosis?

No. Genetic testing offers pathway-level context about your biology, not a diagnosis. Aortic stenosis is diagnosed by a clinician using a physical exam and imaging such as echocardiography. Genetics can describe inherited tendencies but cannot confirm, rule out, treat, or manage the condition.

Why does lipoprotein(a) matter for the aortic valve?

Lipoprotein(a), set largely by the LPA gene, is a cholesterol-carrying particle that is roughly 80–90% inherited and stable across life. Studies link higher Lp(a) to greater aortic valve calcification, so knowing your level can inform a broader cardiovascular risk conversation with your provider.

Want pathway-level context on your cardiovascular genetics? Take the Precision Peptide Genetic Test to explore your pathway-level genetics and bring that context to your next provider conversation.

The Precision Peptide Genetic Test analyzes how your genes influence peptide-related biological pathways. It does not recommend, prescribe, or determine which peptides you should use. Consult a qualified healthcare provider before beginning any peptide protocol.

This article is part of the PlexusDx Education Hub. Browse all Heart & Cardiovascular Health education

Medical and Editorial Standards

Medical review process: This article was reviewed for medical accuracy, scientific clarity, evidence alignment, and appropriate discussion of genetics, medications, supplements, biomarkers, and health-related claims.

Sources and evidence: PlexusDx educational content is developed using peer-reviewed research, clinical literature, reputable medical references, and, where applicable, public health or regulatory guidance. References are included at the end of the article when scientific, medical, or health-related claims are discussed.

Commercial transparency: PlexusDx offers genetic testing, blood biomarker testing, personalized supplement recommendations, and related precision wellness services. Product mentions are intended to help readers understand available options and should not be interpreted as medical advice.

Important disclaimer: PlexusDx educational content is for informational purposes only and should not be used as a substitute for professional medical advice, diagnosis, or treatment. Always consult a qualified healthcare provider before making decisions about medications, supplements, genetic testing, lab testing, or health-related care.